Federal contract award
80NSSC23CA171
E014042 SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | National Aeronautics and Space Administration |
| Office | NASA SHARED SERVICES CENTER |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AJ14 — GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; R&D ADMINISTRATIVE EXPENSES |
| Parent award / vehicle | Not reported |
| Set-aside | SMALL BUSINESS SET ASIDE - TOTAL |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $5.4M |
| Current contract value | $9.6M |
| Potential contract value / ceiling | $9.6M |
| Start date | Jul 10, 2023 |
| Current end date | Jul 19, 2028 |
| Potential end date | Jul 19, 2028 |
| Latest award activity | Aug 20, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 12 of 12 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 20, 2026 | P00011 | $0 | SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE |
| Jun 30, 2026 | P00010 | $0 | SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE |
| Jun 16, 2026 | P00009 | $1.9M | SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE |
| Apr 7, 2026 | P00008 | $0 | SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE |
| Feb 24, 2026 | P00007 | $1.4M | SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE |
| Jan 26, 2026 | P00006 | $0 | SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE |
| Jan 15, 2026 | P00005 | $600.0K | SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE |
| Mar 27, 2025 | P00004 | $0 | SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE |
| Jan 29, 2025 | P00003 | $600.0K | SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE |
| Jul 30, 2024 | P00002 | $0 | SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE |
| Oct 24, 2023 | P00001 | $0 | SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE |
| Jul 10, 2023 | 0 | $995.2K | E014042 SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE |
Estimated positioning window
Jul 19, 2027 – Jan 19, 2028
60/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 60/100. Available recorded signals: 55 points.
- Contract end 2028-07-19 (633 days from calculation)
- +25 points
- 1170 historical awards in this buyer and category group
- +15 points
- 12 recorded award transactions
- +10 points
- Latest award action: 2026-08-20
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.